Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 29,812	$ 33,180
Short-term investments	99,837	202,522
Prepaid expenses and other current assets	12,470	5,914
Total current assets	142,119	241,616
Property and equipment, net	716	100
In-process R&D	11,249	11,636
Other non-current assets	1,849	84
Total assets	155,933	253,436
Current liabilities:
Accounts payable	4,442	5,757
Accrued expenses and other current liabilities	12,188	14,639
Total current liabilities	16,630	20,396
Long-term liabilities:
Long-term debt	30,242	29,907
Other long-term liabilities	1,211	0
Total liabilities	48,083	50,303
Commitments and Contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.001 par value, 600,000,000 authorized as of September 30, 2026 and 300,000,000 authorized as of December 31, 2025; 205,536,152 and 204,567,283 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	204	204
Additional paid-in capital	837,031	811,103
Accumulated other comprehensive loss	(797)	(87)
Accumulated deficit	(728,588)	(608,087)
Total stockholders’ equity	107,850	203,133
Total liabilities and stockholders’ equity	$ 155,933	$ 253,436

In-process research and development.

No definition available.

Name:	svra_InProcessResearchAndDevelopment
Namespace Prefix:	svra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).